<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:af57952e-ca1a-4642-8f6b-00c958350e18,g:d78cb290-380e-431e-92ad-0630f882f811,d:ec38d79f43aa48a9895a513ffb68f215--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rxrx-20230113</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV80L2ZyYWc6OTU0MThjN2VmZmU3NDkzZGFhZjEzMDhiM2ZiYjVmYTMvdGFibGU6YTU1MmQxYjAwNWNiNGVhNzk4MjhmNTVlNTUzNDA4YzcvdGFibGVyYW5nZTphNTUyZDFiMDA1Y2I0ZWE3OTgyOGY1NWU1NTM0MDhjN18xLTEtMS0xLTc3NzIy_a6e1ba10-cc32-48fa-97a1-68fc86df203d">0001601830</ix:nonNumeric><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV80L2ZyYWc6OTU0MThjN2VmZmU3NDkzZGFhZjEzMDhiM2ZiYjVmYTMvdGFibGU6YTU1MmQxYjAwNWNiNGVhNzk4MjhmNTVlNTUzNDA4YzcvdGFibGVyYW5nZTphNTUyZDFiMDA1Y2I0ZWE3OTgyOGY1NWU1NTM0MDhjN18yLTEtMS0xLTc3NzIy_ee277425-3fec-4125-997e-9cba9d821927">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rxrx-20230113.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601830</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-13</xbrli:startDate><xbrli:endDate>2023-01-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iec38d79f43aa48a9895a513ffb68f215_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8xNjU3_993f762a-8399-4050-8980-7b89f42f0ece">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of The Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8yMjc_513b32dc-46fd-4f34-b923-aea74a7f8f0b">January&#160;13, 2023</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8yMzE_f3f2ef3e-5396-4cf0-af6d-7e9f862ea811">RECURSION PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGFibGU6NjQ5NTZlMDIzOGE2NDAxNzlhZmIyNDdiMDVjYjdmZDAvdGFibGVyYW5nZTo2NDk1NmUwMjM4YTY0MDE3OWFmYjI0N2IwNWNiN2ZkMF8wLTAtMS0xLTc3NzIy_128b5858-5e12-4eca-907d-a28afa25c93d">Delaware</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGFibGU6NjQ5NTZlMDIzOGE2NDAxNzlhZmIyNDdiMDVjYjdmZDAvdGFibGVyYW5nZTo2NDk1NmUwMjM4YTY0MDE3OWFmYjI0N2IwNWNiN2ZkMF8wLTItMS0xLTc3NzIy_8ecd5bf2-65ec-4152-84dc-49910b219016">001-40323</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;<ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGFibGU6NjQ5NTZlMDIzOGE2NDAxNzlhZmIyNDdiMDVjYjdmZDAvdGFibGVyYW5nZTo2NDk1NmUwMjM4YTY0MDE3OWFmYjI0N2IwNWNiN2ZkMF8wLTQtMS0xLTc3NzIy_b1e803a0-72ea-45d4-baf9-8671fe3b1b92">46-4099738</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8yOTQ_be2bc364-c0a2-49ab-bd14-e2053b21803f">41 S Rio Grande Street</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8yOTc_8f2b2b19-aebe-417d-bd06-c0de9d7ca2f4">Salt Lake City,</ix:nonNumeric> <ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8zMDA_8c5ed6d7-5ea3-4dcb-b7f3-00b7919cfca0">UT</ix:nonNumeric> <ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8zMDM_a2bd1b80-f0a4-464a-92bd-d266dcba160b">84101</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8zNjA_d524e523-1bee-47fd-849d-466451ce680e">385</ix:nonNumeric>) <ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8zNjQ_8183e2a7-48b0-4c21-a242-25ff5463a25e">269 - 0203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8xNjUy_31a9838f-d8c6-46e3-8611-1a74eb8cfce2">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8xNjUz_23b4b9a9-a9c5-4e45-acb3-72801d409033">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8xNjU0_15cd35c7-7e36-4b4b-85dc-b0e01fb50202">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl8xNjU1_89e4d426-0b15-4ac8-8f5a-2164b9491e1d">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGFibGU6ZmExNDFjYTMyMjgxNGRlZWIzZDIzN2VkOTc3OTQwYWEvdGFibGVyYW5nZTpmYTE0MWNhMzIyODE0ZGVlYjNkMjM3ZWQ5Nzc5NDBhYV8xLTAtMS0xLTc3NzIy_81bd75b7-c45e-47a2-9e65-443289aac66b">Class A Common Stock, par value $0.00001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGFibGU6ZmExNDFjYTMyMjgxNGRlZWIzZDIzN2VkOTc3OTQwYWEvdGFibGVyYW5nZTpmYTE0MWNhMzIyODE0ZGVlYjNkMjM3ZWQ5Nzc5NDBhYV8xLTEtMS0xLTc3NzIy_b756560d-43ed-4353-b26a-45acfff64fa4">RXRX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGFibGU6ZmExNDFjYTMyMjgxNGRlZWIzZDIzN2VkOTc3OTQwYWEvdGFibGVyYW5nZTpmYTE0MWNhMzIyODE0ZGVlYjNkMjM3ZWQ5Nzc5NDBhYV8xLTItMS0xLTc3NzIy_44c6b41f-c867-4641-820f-1d71c8b0964e">Nasdaq Global Select Market</ix:nonNumeric> </span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i54e82698ef6a4609b5b73a4b50025e72_D20230113-20230113" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVjMzhkNzlmNDNhYTQ4YTk4OTVhNTEzZmZiNjhmMjE1L3NlYzplYzM4ZDc5ZjQzYWE0OGE5ODk1YTUxM2ZmYjY4ZjIxNV8xL2ZyYWc6MTdhNjRmMTczY2IzNDkyMGE3NzJlMjc3NDZkZDdjZGIvdGV4dHJlZ2lvbjoxN2E2NGYxNzNjYjM0OTIwYTc3MmUyNzc0NmRkN2NkYl81NDk3NTU4MTU1NjI_b8820616-bd8e-4a87-865b-804051f62ee6">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div><span><br/></span></div><div id="iec38d79f43aa48a9895a513ffb68f215_10"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.01. Regulation FD Disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louisa Daniels has ended her employment as Chief Legal Officer and General Counsel of Recursion Pharmaceuticals, Inc. (the &#8220;Company&#8221;). We thank Ms. Daniels for her substantial contributions to our mission, which include guiding the Company through its transition into a public company and building a highly effective legal team.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on January 13, 2023, the Company appointed Nathan Hatfield to the position of Senior Vice President, Head of Legal. Mr. Hatfield will assume all responsibilities of Ms. Daniels, including joining our executive team. Mr. Hatfield has held several critical leadership positions since joining the Company in early 2017, most recently Senior Vice President of Legal and Associate General Counsel. Prior to that, Mr. Hatfield was a corporate and securities attorney at Wilson Sonsini, where he represented venture-backed technology and life science companies through all stages of growth. Mr. Hatfield has a bachelor&#8217;s degree and a master&#8217;s degree in Business Administration and a Juris Doctorate from the University of Washington.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished pursuant to Item 7.01 on this Form 8-K, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div id="iec38d79f43aa48a9895a513ffb68f215_13"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div id="iec38d79f43aa48a9895a513ffb68f215_16"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on January&#160;13, 2023.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RECURSION PHARMACEUTICALS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Gibson</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christopher Gibson</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer </span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "rxrx-20230113.htm", "description": "8-K", "secsgml_size_bytes": 29483}]
{"company-data": {"conformed-name": "RECURSION PHARMACEUTICALS, INC.", "cik": "0001601830", "assigned-sic": "2836", "irs-number": "464099738", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-40323", "film-number": "23529391"}, "business-address": {"street1": "41S RIO GRANDE STREET", "city": "SALT LAKE CITY", "state": "UT", "zip": "84101", "phone": "(385) 269-0203"}, "mail-address": {"street1": "41S RIO GRANDE STREET", "city": "SALT LAKE CITY", "state": "UT", "zip": "84101"}, "former-company": {"former-conformed-name": "Recursion Pharmaceuticals, LLC", "date-changed": "20140305"}}
rxrx-20230113
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 13, 2023
RECURSION PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-40323
46-4099738
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
41 S Rio Grande Street
Salt Lake City,
UT
84101
(Address of principal executive offices) (Zip code)
(
385
)
269 - 0203
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.00001 per share
RXRX
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Item 7.01. Regulation FD Disclosure.
Louisa Daniels has ended her employment as Chief Legal Officer and General Counsel of Recursion Pharmaceuticals, Inc. (the "Company"). We thank Ms. Daniels for her substantial contributions to our mission, which include guiding the Company through its transition into a public company and building a highly effective legal team.
Also, on January 13, 2023, the Company appointed Nathan Hatfield to the position of Senior Vice President, Head of Legal. Mr. Hatfield will assume all responsibilities of Ms. Daniels, including joining our executive team. Mr. Hatfield has held several critical leadership positions since joining the Company in early 2017, most recently Senior Vice President of Legal and Associate General Counsel. Prior to that, Mr. Hatfield was a corporate and securities attorney at Wilson Sonsini, where he represented venture-backed technology and life science companies through all stages of growth. Mr. Hatfield has a bachelor's degree and a master's degree in Business Administration and a Juris Doctorate from the University of Washington.
The information furnished pursuant to Item 7.01 on this Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on January 13, 2023.
RECURSION PHARMACEUTICALS, INC.
By:
/s/ Christopher Gibson
Christopher Gibson
Chief Executive Officer